Johnson & Johnson will pay $6.5 billion to resolve nearly all talc ovarian cancer lawsuits in U.S.

Johnson & Johnson announced it will pay $6.5 billion to settle nearly all U.S. lawsuits alleging its talc-based products caused ovarian cancer. The settlement will be handled through a third bankruptcy filing of its subsidiary, LTL Management. This arrangement aims to address all current and future ovarian cancer claims, with a three-month voting period for claimants to reach a consensus. The company also noted that it has already resolved 95% of the lawsuits related to mesothelioma, which will be handled separately from this settlement.